India & Cipla
10 shared events · Importance 5 · Last updated Sep 10, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Domestic
India: India is experiencing a severe shortage of platinum-based cancer drugs, impacting its healthcare system and patients. The government's price caps on medicines are contributing to the supply crunch.
Cipla: Cipla>>> is one of the generic drugmakers in India>>> that produces platinum-based chemotherapy, and its production is affected by the platinum shortage and price caps.
Jun 09, 2026 · 9 articles
Business
India: Cipla's India business posted record quarterly sales of Rs 3,452 crore, growing 12%, with strong performance in chronic therapies.
Cipla: Cipla reported a 39% net profit decline due to North America sales drop and higher expenses; its India business achieved record sales. The company appointed a new CFO and expects sequential recovery in North America.
Jul 23, 2026 · 6 articles
Business
India: India is the home country of Cipla and several competing firms, and the deal reflects India's growing role in global biosimilar development.
Cipla: Cipla, through its subsidiary Invagen, is the licensee and commercializer of QL2107 in the US, strengthening its oncology biosimilar portfolio and potential future revenue.
Sep 03, 2026 · 6 articles
Domestic
India: India is the national context for the roadshow, which aims to boost investment in India — Gujarat, contributing to national economic growth.
Cipla: Cipla, a pharmaceutical company, was represented, indicating interest in India — Gujarat's pharmaceutical sector.
Sep 02, 2026 · 9 articles
Regulatory
India: The regulatory action in India reflects the country's enforcement of pharmaceutical laws, potentially affecting the operating environment for drug companies. It underscores the importance of compliance with Indian drug regulations.
Cipla: Cipla's Pune C&F unit lost its drug sale licences due to regulatory violations, leading to potential distribution disruptions and reputational damage. The company faces scrutiny over compliance practices, but the financial impact is expected to be manageable.
Aug 28, 2026 · 52 articles
Tech
India: India is the jurisdiction where the therapy received regulatory approval and entered clinical practice, highlighting the country's evolving regenerative medicine landscape.
Cipla: Cipla is making the approved stem cell therapy available, positioning it as a distributor of a novel regenerative treatment in India. This could modestly enhance its specialty portfolio and reputation in advanced therapies.
Sep 10, 2026 · 6 articles
Regulatory
India: India's regulatory framework is being tested; the case could clarify the applicability of drug laws to duty-free shops.
Cipla: Cipla is mentioned only as former employer of Murali Neelakantan; not directly involved.
Jul 07, 2026 · 17 articles
Business
India: The appointment is part of IBSFINtech's global expansion, which originates from India and may contribute to the country's fintech ecosystem.
Cipla: Cipla is mentioned as a client of IBSFINtech; no direct impact from the appointment.
Sep 03, 2026 · 6 articles
Business
Cipla: Cipla entered into an exclusive agreement with Pfizer India to market, distribute, and sell four of Pfizer's brands in India, expanding its presence in key therapy areas and leveraging its distribution capabilities.
Dec 19, 2025 · 6 articles
Regulatory
Cipla: Achin Gupta, MD & Global CEO of Cipla, delivered the vote of thanks at the India Pharma 2026 conference.
Apr 12, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how India and Cipla interact across events, view sentiment trends, and discover connected entities.
Open Dashboard